SLRX Salarius Pharmaceuticals

Salarius Pharmaceuticals to Present at BIO Investor Forum Digital

Salarius Pharmaceuticals to Present at BIO Investor Forum Digital
EN
13/10/2020

Underlying

SLRXSalarius Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Salarius Pharmaceuticals

 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Re...

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement. This follows the Company’s announcement on September 9, 2025 that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement. “Salarius is now fully compliant with all Nasdaq listing...

October 13, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Pr...

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement. By meeting the Minimum Bid Price Requirement, Salarius has achieved one of the milestones in regaining compliance with all Nasdaq continued listing standards. As previously disclosed on August 27, 2025, Salarius h...

September 9, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Time, on August 15, 2025. Beginning with the opening of trading on August 18, 2025, Salarius’ common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new C...

August 14, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Granted Additional Extension to Regain Compli...

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) by early August 2025. On April ...

July 14, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in...

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Therapeutics HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SLRX) (Salarius or the Company) announces that two animal studies recently published in peer-reviewed journals provide additional insight into the role of inhibiting lysine-demethylase...

July 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch